Estructura del grupo
17 empresas en 8 países
17 empresas en 8 países
Una cuenta gratuita para las apps de Prognia: Ward para estudiar, Osler para respuestas clínicas con sus fuentes y la red para encontrar a tus colegas.
Prognia forma los grupos a partir de los nombres que publican las autoridades reguladoras y de los vínculos entre empresas; no son una estructura societaria oficial.
Todos los medicamentos de todas las empresas del grupo, primero los vigentes.
1–25 de 541
| Medicamento | Principio activo | País | Estado | Autorización |
|---|---|---|---|---|
| ACANYA2.5%; 1.2% base · GEL | Benzoyl peroxide, Clindamycin | Estados Unidos | Comercializado | 2008 |
| ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE2%; 0.79% · Solution/drops | Acetic acid, Glacial, Aluminum | Estados Unidos | No comercializado | 1994 |
| Acetilsalicilatna kiselina Bausch Health 100 mg želučanootporne tableteželučanootporna tableta | Acetylsalicylic acid | Croacia | No comercializado | 2025 |
| Acetilsalicilatna kiselina Bausch Health 75 mg želučanootporne tableteželučanootporna tableta | Acetylsalicylic acid | Croacia | No comercializado | 2025 |
| ACZONE5 % / w/w · Gel | Dapsone | Canadá | Comercializado | 2011 |
| AIROMIR100 mcg / act · Aerosol (Metered-Dose) | Salbutamol | Canadá | No comercializado | 1998 |
| AKNE-MYCIN2% · Ointment | Erythromycin | Estados Unidos | No comercializado | 1985 |
| ALAWAY0.025% base · Solution/drops | Ketotifen | Estados Unidos | Comercializado | 2006 |
| ALDARA5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Cream | Imiquimod | Estados Unidos | No comercializado | 1997 |
| ALDARA P5 % · Cream | Imiquimod | Canadá | Comercializado | 1999 |
| ALREX0.2% · Suspension/drops | Loteprednol | Estados Unidos | Comercializado | 1998 |
| ALREX0.2 % / w/v · Suspension | Loteprednol | Canadá | Comercializado | 2009 |
| ALTACE1.25 mg · Capsule | Ramipril | Canadá | Comercializado | 1997 |
| ALTACE2.5 mg · Tablet | Ramipril | Canadá | Autorizado | |
| ALTACE5 mg · Capsule | Ramipril | Canadá | Comercializado | 1997 |
| ALTACE5 mg · Tablet | Ramipril | Canadá | Autorizado | |
| ALTACE15 mg · Capsule | Ramipril | Canadá | No comercializado | 2006 |
| ALTACE10 mg · Tablet | Ramipril | Canadá | Autorizado | |
| ALTACE10 mg · Capsule | Ramipril | Canadá | Comercializado | 1997 |
| ALTACE1.25 mg · Tablet | Ramipril | Canadá | Autorizado | |
| ALTACE2.5 mg · Capsule | Ramipril | Canadá | Comercializado | 1997 |
| ALTACE HCT25 mg + 10 mg · Tablet | Hydrochlorothiazide, Ramipril | Canadá | No comercializado | 2006 |
| ALTACE HCT25 mg + 5 mg · Tablet | Hydrochlorothiazide, Ramipril | Canadá | No comercializado | 2006 |
| ALTACE HCT12.5 mg + 2.5 mg · Tablet | Hydrochlorothiazide, Ramipril | Canadá | No comercializado | 2006 |
| ALTACE HCT12.5 mg + 10 mg · Tablet | Hydrochlorothiazide, Ramipril | Canadá | No comercializado | 2006 |
Dónde es titular o fabricante de medicamentos, y cuántos están vigentes.
| País | Medicamentos | Vigentes | Anteriores | Empresas |
|---|---|---|---|---|
| Canadá | 256 | 210 | 46 | EmpresasTodos los medicamentos |
| Estados Unidos | 138 | 138 | 0 | EmpresasTodos los medicamentos |
| Países Bajos | 46 | 46 | 0 | EmpresasTodos los medicamentos |
| España | 43 | 37 | 6 | EmpresasTodos los medicamentos |
| Croacia | 32 | 32 | 0 | EmpresasTodos los medicamentos |
| Singapur | 12 | 12 | 0 | EmpresasTodos los medicamentos |
| Rumanía | 8 | 0 | 8 | EmpresasTodos los medicamentos |
| Unión Europea (EMA) | 3 | 2 | 1 | EmpresasTodos los medicamentos |
| Arabia Saudí | 3 | 3 | 0 | EmpresasTodos los medicamentos |
También en los registros de Brasil, Colombia, Francia, Italia, Malasia, Reino Unido, Serbia, Suecia
Los grupos ATC a los que pertenecen la mayoría de sus medicamentos, de mayor a menor.
Los principios activos presentes en la mayoría de sus medicamentos.
Cómo lo escriben los registros, normalizado: sin forma jurídica, tildes ni mayúsculas.
Recopilado por Prognia a partir de los registros públicos de medicamentos y empresas que aparecen abajo. No se usan logotipos.
Prognia forma los grupos a partir de los nombres que publican las autoridades reguladoras y de los vínculos entre empresas; no son una estructura societaria oficial.
Source: European Medicines Agency (EPAR data).
Licencia: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licencia: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licencia: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licencia: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licencia: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licencia: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licencia: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licencia: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos; source update 2026-09-16; acquired 2026-10-08.
Licencia: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licencia: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes, dataset i7cb-raxc, rowsUpdatedAt 1792152574, acquired 2026-10-26; original values retained.
Licencia: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licencia: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licencia: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licencia: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licencia: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licencia: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licencia: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licencia: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licencia: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licencia: CC BY 4.0; AIFA published open-data catalog
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licencia: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licencia: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licencia: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licencia: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licencia: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licencia: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licencia: Creative Commons Attribution 4.0 International (CC BY 4.0)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licencia: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licencia: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Informa de un error o solicita la retiradaLas correcciones de la propia empresa son bienvenidas.
Mantenga correctos los medicamentos de Bausch en Prognia, vea cómo los consultan los profesionales y responda a lo que preguntan. Una llamada de 20 minutos, en inglés.
Reservar una llamadaGrupos farmacéuticos conocidos, cada uno con todas sus empresas.